Original title: Merck: There is still a huge data gap in the single-dose plan of the HPV vaccine, Wantai Bio’s first-quarter net profit surged in response to the sharp drop in the stock price
On April 17, the Red Star Capital Bureau reported that a single-dose HPV vaccine proposed by the WHO can provide reliable protection. The media spokesperson of Merck headquarters responded on April 16.
A spokesman for the media at Merck’s headquarters pointed out,“The draft high-level recommendations of the SAGE (Strategic Advisory Group of Experts on Immunization) are not final and are subject to review by the Director-General of the World Health Organization. These reports are only considered final when they are published in the Weekly Epidemiological Record.”
A spokesman for the Merck headquarters media also said,There is a huge data gap for single-dose regimens or other regimens that are not currently under regulatory approval。
Just following the WHO released the news that a single-dose HPV vaccine can provide reliable protection, Wantai Bio (603392.SH), a leading stock that fell sharply, not only responded urgently, but also released its first quarterly report for 2022. The report shows that the company achieved operating income of 3.171 billion yuan, a year-on-year increase of 284.85%; realized a net profit attributable to shareholders of the listed company of 1.331 billion yuan, a year-on-year increase of 360.18%.
Merck: Currently two or three doses are more effective
Recently, the WHO SAGE meeting from 4 to 7 April reviewed the evidence for one-dose human papillomavirus (ie HPV) vaccination and concluded that a single dose of HPV vaccine provides reliable protection, comparable to a two- or three-dose vaccination regimen.
The immunization schedule for the 4-valent and 9-valent HPV vaccines approved by the regulator is only two or three doses, depending on the age and dosage plan, according to a daily economic news report.Regulatory approved regimens are backed by strong clinical trials and real-world evidence that two- and three-dose HPV vaccinations have favorable efficacy, efficacy, safety, and long-term persistence for certain HPV-related cancers and diseases .
MSD Graph According to Visual China
The single-dose HPV vaccine regimen is subject to great uncertainty. Currently, data on its long-term protection once morest certain HPV-related cancers and diseases are very limited. Effectiveness in other subgroups such as men and immunocompromised populations.
According to the Securities Times report, Professor Wei Lihui, director of the Colposcopy and Cervical Cancer Pathology Branch (CSCCP) of the China Eugenics Association, said in an interview on April 16 that the vaccination rate of 9-14-year-old girls who benefited the most from the HPV vaccine Only less than 2%, so three doses of full vaccination are still recommended.
Vaccine leading stocks plummeted collectively
Second-price and other income increased, Wantai’s first-quarter net profit increased by 360%
On April 14, following the news that the single-dose HPV vaccine can effectively prevent cervical cancer was released, the stock prices of Zhifei Bio (300122.SZ), Wantai Bio (603392.SH), and Watson Bio (300142.ZS) plunged. At the close, the market value of the three companies evaporated by nearly 50 billion yuan.
However, by the second day, the company’s stock price rebounded. As of the close of the previous trading day, Watson Bio rose 12.52% to 55.26 yuan per share; Wantai Bio rose 4.47% to 269.1 yuan per share; Zhifei Bio was slightly inferior, down 0.02% to 115.98 yuan per share. share.
Wantai Biology immediately made an emergency announcement on the day the news was released, saying that as of now, the company has only obtained a domestic vaccine registration license, and has not yet obtained a foreign country vaccine registration license. The company’s currently approved bivalent HPV vaccine in China is three doses (two doses for women aged 9-14). Before the national policy changes, the company will continue to sell according to the currently approved doses, but in the future, it is not ruled out that the WHO and the domestic government will actively promote the one-dose or two-dose vaccination program.
On the evening of April 15, Wantai Bio disclosed the report for the first quarter of 2022, achieving an operating income of 3.171 billion yuan, a year-on-year increase of 284.85%; the net profit attributable to shareholders of the listed company was 1.331 billion yuan, a year-on-year increase of 360.18%.
The announcement pointed out that the substantial increase in its financial indicators was mainly due to the increase in revenue from bivalent cervical cancer vaccines, reagents and active raw materials.
Red Star News reporter Deng Lingyao
Editor-in-Chief Ren ZhijiangReturn to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.
